MedTrace Logo

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-06-19

Study results available
· View outcomes & findings →

Summary

The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.

Conditions

  • Familial Amyotrophic Lateral Sclerosis

Interventions

DRUG

Pyrimethamine

Open Label, dose escalating,

Sponsors & Collaborators

Principal Investigators

  • Dale J. Lange, M.D. · Hospital for Special Surgery/Weill Cornell Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2014-12-31
Completion
2016-05-31

Countries

  • United States
  • Germany
  • Italy
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01083667 on ClinicalTrials.gov